OBJECTIVES: To gain insight into the natural history and carcinogenesis pathway of Pancreatic Intraepithelial Neoplasia (PanIN) lesions by building a calibrated simulation model of PanIN progression to pancreatic ductal adenocarcinoma (PDAC) METHODS: We revised a previously validated simulation model of solid PDAC, calibrating the model to fit data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program and published literature on PanIN prevalence by age. We estimated the likelihood of progression from PanIN states (1, 2, and 3) to PDAC and the time between PanIN onset and PDAC (dwell time). We evaluated a hypothetical intervention to test for and treat PanIN 3 lesions to estimate the potential benefits from PanIN detection. RESULTS: We estimated the lifetime probability of progressing from PanIN 1 to PDAC to be 1.5% (men), 1.3% (women). Progression from PanIN 1 to PDAC took 33.6 years and 35.3 years, respectively, and from PanIN 3 to PDAC took 11.3 years and 12.3 years. A hypothetical test for PanIN 3 detection and treatment could provide a maximum, average life expectancy gain of 40 days. CONCLUSIONS: Our modeling analysis estimates PanINs have a relatively indolent course to PDAC, supporting the feasibility of potential future early detection strategies.
OBJECTIVES: To gain insight into the natural history and carcinogenesis pathway of Pancreatic Intraepithelial Neoplasia (PanIN) lesions by building a calibrated simulation model of PanIN progression to pancreatic ductal adenocarcinoma (PDAC) METHODS: We revised a previously validated simulation model of solid PDAC, calibrating the model to fit data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program and published literature on PanIN prevalence by age. We estimated the likelihood of progression from PanIN states (1, 2, and 3) to PDAC and the time between PanIN onset and PDAC (dwell time). We evaluated a hypothetical intervention to test for and treat PanIN 3 lesions to estimate the potential benefits from PanIN detection. RESULTS: We estimated the lifetime probability of progressing from PanIN 1 to PDAC to be 1.5% (men), 1.3% (women). Progression from PanIN 1 to PDAC took 33.6 years and 35.3 years, respectively, and from PanIN 3 to PDAC took 11.3 years and 12.3 years. A hypothetical test for PanIN 3 detection and treatment could provide a maximum, average life expectancy gain of 40 days. CONCLUSIONS: Our modeling analysis estimates PanINs have a relatively indolent course to PDAC, supporting the feasibility of potential future early detection strategies.
Authors: Pari V Pandharipande; Curtis Heberle; Emily C Dowling; Chung Yin Kong; Angela Tramontano; Katherine E Perzan; William Brugge; Chin Hur Journal: Radiology Date: 2014-11-12 Impact factor: 11.105
Authors: Hermann Brenner; Lutz Altenhofen; Alexander Katalinic; Iris Lansdorp-Vogelaar; Michael Hoffmeister Journal: Am J Epidemiol Date: 2011-10-07 Impact factor: 4.897
Authors: Jordan M Cloyd; Hop S Tran Cao; Maria Q B Petzel; Jason W Denbo; Nathan H Parker; Graciela M Nogueras-González; Joseph S Liles; Michael P Kim; Jeffrey E Lee; Jean-Nicolas Vauthey; Thomas A Aloia; Jason B Fleming; Matthew H G Katz Journal: J Surg Oncol Date: 2016-11-11 Impact factor: 3.454
Authors: Spring Holter; Ayelet Borgida; Anna Dodd; Robert Grant; Kara Semotiuk; David Hedley; Neesha Dhani; Steven Narod; Mohammad Akbari; Malcolm Moore; Steven Gallinger Journal: J Clin Oncol Date: 2015-05-04 Impact factor: 44.544
Authors: Marcia Irene Canto; Jose Alejandro Almario; Richard D Schulick; Charles J Yeo; Alison Klein; Amanda Blackford; Eun Ji Shin; Abanti Sanyal; Gayane Yenokyan; Anne Marie Lennon; Ihab R Kamel; Elliot K Fishman; Christopher Wolfgang; Matthew Weiss; Ralph H Hruban; Michael Goggins Journal: Gastroenterology Date: 2018-05-24 Impact factor: 22.682
Authors: Ioannis T Konstantinidis; Eduardo F Vinuela; Laura H Tang; David S Klimstra; Michael I D'Angelica; Ronald P Dematteo; T Peter Kingham; Yuman Fong; William R Jarnagin; Peter J Allen Journal: Ann Surg Oncol Date: 2013-06-08 Impact factor: 5.344
Authors: C Bosetti; V Rosato; D Li; D Silverman; G M Petersen; P M Bracci; R E Neale; J Muscat; K Anderson; S Gallinger; S H Olson; A B Miller; H Bas Bueno-de-Mesquita; G Scelo; V Janout; I Holcatova; P Lagiou; D Serraino; E Lucenteforte; E Fabianova; P A Baghurst; W Zatonski; L Foretova; E Fontham; W R Bamlet; E A Holly; E Negri; M Hassan; A Prizment; M Cotterchio; S Cleary; R C Kurtz; P Maisonneuve; D Trichopoulos; J Polesel; E J Duell; P Boffetta; C La Vecchia; P Ghadirian Journal: Ann Oncol Date: 2014-07-23 Impact factor: 32.976
Authors: Thomas A Laffan; Karen M Horton; Alison P Klein; Bruce Berlanstein; Stanley S Siegelman; Satomi Kawamoto; Pamela T Johnson; Elliot K Fishman; Ralph H Hruban Journal: AJR Am J Roentgenol Date: 2008-09 Impact factor: 3.959
Authors: Mary Linton B Peters; Andrew Eckel; Anna Lietz; Claudia Seguin; Peter Mueller; Chin Hur; Pari V Pandharipande Journal: Pancreatology Date: 2022-05-31 Impact factor: 3.977
Authors: Luke Ternes; Ge Huang; Christian Lanciault; Guillaume Thibault; Rachelle Riggers; Joe W Gray; John Muschler; Young Hwan Chang Journal: Sci Rep Date: 2020-12-01 Impact factor: 4.379
Authors: Andrew McGuigan; Paul Kelly; Richard C Turkington; Claire Jones; Helen G Coleman; R Stephen McCain Journal: World J Gastroenterol Date: 2018-11-21 Impact factor: 5.742
Authors: Muhammad Nadeem Yousaf; Fizah S Chaudhary; Amrat Ehsan; Alejandro L Suarez; Thiruvengadam Muniraj; Priya Jamidar; Harry R Aslanian; James J Farrell Journal: BMJ Open Gastroenterol Date: 2020-05